纳米银体外对三种微生物的抑制作用及机制

目的探讨纳米银广谱的抗菌作用及机制。方法以金黄色葡萄球菌、大肠埃希菌及白假丝酵母菌为研究对象,采用涂布法检测纳米银的杀菌作用,利用细菌呼吸链脱氢酶活性检测及透射电镜探讨纳米银抑菌的作用机制。结果≥0.05μg/mL的纳米银对金黄色葡萄球菌、大肠埃希菌及白假丝酵母菌具有明显的杀菌作用;5μg/mL的纳米银对金黄色葡萄球菌、大肠埃希菌及白假丝酵母菌作用60、30、15和5min均有明显的杀菌作用;纳米银对金黄色葡萄球菌、大肠埃希菌的呼吸链脱氢酶活性具有明显的抑制作用;纳米银对金黄色葡萄球菌、大肠埃希菌和白假丝酵母菌的菌体形态具有明显的破坏作用。结论纳米银对金黄色葡萄球菌、大肠埃希菌和白假丝酵母菌具有高效、迅速及广谱的杀菌作用,这些作用可能与纳米银的多靶位作用机制有关。     

新型纳米银体外广谱抗菌作用及机制

目的探讨新型纳米银体外对临床感染常见细菌的广谱抗菌作用及机制。方法选择临床常见的金黄色葡萄球菌、大肠埃希菌、肺炎克雷伯菌、鲍曼不动杆菌和铜绿假单胞菌为研究对象,采用平板涂布法检测新型纳米银的广谱抗菌作用,利用透射电镜观察细菌呼吸链脱氢酶活性和细菌细胞膜的渗漏性改变,探讨新型纳米银的抗菌作用机制。结果新型纳米银浓度超过0.05μg/mL对临床感染常见的5种细菌具有明显的抑制作用;浓度5μg/mL的新型纳米银体外作用临床感染常见细菌5min,可100%抑制细菌生长。电镜观察新型纳米银可吸附在金黄色葡萄球菌和大肠埃希菌的菌体表面,改变了细菌形态结构。新型纳米银可明显抑制金黄色葡萄球菌与大肠埃希菌的呼吸链脱氢酶活性;较高浓度的新型纳米银可破坏金黄色葡萄球菌与大肠埃希菌的细胞膜,导致细菌胞浆内容物外漏。结论新型纳米银对临床感染常见细菌具有广谱高效的抗菌作用,其作用机制可能与新型纳米银吸附在细菌表面,抑制细菌表面生物大分子功能或活性有关,研究结果为新型纳米银抗菌作用的深入研究及临床应用提供了实验依据。     

载银纳米抗菌复合骨填充材料体外抗菌性能研究

目的探讨新型载银纳米抗菌复合骨填充材料(TiO2-Ag-nHA/PA66)的体外抗菌性能。方法采用抑菌环试验及菌落总数测定法检测不同纳米抗菌复合骨填充材料(A1、A2、A3)对金黄色葡萄球菌及大肠埃希菌的体外抗菌效果;扫描电镜观察其对细菌的抗粘附作用。结果抑菌环试验显示,不同载银纳米抗菌复合骨填充材料对金黄色葡萄球菌和大肠埃希菌均形成明显的抑菌环,以作用24 h抑菌环直径最大,并随作用时间延长,抑菌环直径逐渐缩小。其中银含量为0.64%(质量比)的材料A3的抗菌作用最明显,持续时间最长,其对金黄色葡萄球菌和大肠埃希菌的抑菌作用持续时间分别达到33 d和24 d;菌落总数测定法显示细菌与材料A3接触24 h后,对金黄色葡萄球菌和大肠埃希菌的抗菌率分别为94.18%和85.96%;扫描电镜发现载银材料能够明显减少细菌在材料表面的粘附。结论载银纳米抗菌复合骨填充材料体外对金黄色葡萄球菌及大肠埃希菌有明显抗菌作用,为其应用于慢性骨髓炎术后骨缺损修复提供理论依据。     

黑大蒜提取物联合抗生素对金黄色葡萄球菌和肠埃希菌的体外抗菌作用研究

评价黑大蒜提取物分别与头孢唑林或庆大霉素联合应用,对金黄色葡萄球菌和大肠埃希菌的体外抗菌效应。采用液体稀释法分别测定黑大蒜提取物对金黄色葡萄球菌和大肠埃希菌的最低抑菌浓度（MIC）。采用棋盘法设计,微量肉汤稀释法测定黑大蒜提取物联合头孢唑林或庆大霉素对金黄色葡萄球菌和大肠埃希菌的MIC,并计算部分抑菌浓度（FIC指数）。测定黑大蒜提取物对金黄色葡萄球菌和大肠埃希菌的时间-杀菌曲线。黑大蒜提取物对金黄色葡萄球菌的MIC为256μg/mL,黑大蒜提取物对大肠埃希菌的MIC为256μg/mL。时间-杀菌曲线结果显示黑大蒜提取物对金黄色葡萄球菌和大肠埃希菌的抑菌作用呈现较强的浓度依赖性。黑大蒜提取物联合头孢唑林后对金黄色葡萄球菌的FIC指数为0.75;黑大蒜提取物联合庆大霉素后对大肠埃希菌的FIC指数为0.5。黑大蒜提取物与头孢唑林或庆大霉素联合用药,可明显降低抗生素对金黄色葡萄球菌和大肠埃希菌的MIC,表现为相加和协同效应。     

黑大蒜提取物联合抗生素对金黄色葡萄球菌和大肠埃希菌的体外抗菌作用研究

评价黑大蒜提取物分别与头孢唑林或庆大霉素联合应用,对金黄色葡萄球菌和大肠埃希菌的体外抗菌效应。采用液体稀释法分别测定黑大蒜提取物对金黄色葡萄球菌和大肠埃希菌的最低抑菌浓度(MIC)。采用棋盘法设计,微量肉汤稀释法测定黑大蒜提取物联合头孢唑林或庆大霉素对金黄色葡萄球菌和大肠埃希菌的MIC,并计算部分抑菌浓度(FIC指数)。测定黑大蒜提取物对金黄色葡萄球菌和大肠埃希菌的时间-杀菌曲线。黑大蒜提取物对金黄色葡萄球菌的MIC为256μg/mL,黑大蒜提取物对大肠埃希菌的MIC为256μg/mL。时间-杀菌曲线结果显示黑大蒜提取物对金黄色葡萄球菌和大肠埃希菌的抑菌作用呈现较强的浓度依赖性。黑大蒜提取物联合头孢唑林后对金黄色葡萄球菌的FIC指数为0.75;黑大蒜提取物联合庆大霉素后对大肠埃希菌的FIC指数为0.5。黑大蒜提取物与头孢唑林或庆大霉素联合用药,可明显降低抗生素对金黄色葡萄球菌和大肠埃希菌的MIC,表现为相加和协同效应。     

乳酸杆菌细胞裂解物对金黄色葡萄球菌、大肠埃希菌的抑制作用

目的探讨乳杆菌DM8909裂解物在体内外对金黄色葡萄球菌、大肠埃希菌的抑制作用。方法通过对乳杆菌超声波破碎制成裂解物,分别用乳杆菌裂解物原液、裂解物稀释液、发酵上清液、乳杆菌活菌制剂进行体内、体外实验,观察乳杆菌各成分对金黄色葡萄球菌、大肠埃希菌的抑制作用。结果德氏乳酸杆菌裂解物对金黄色葡萄球菌、大肠埃希菌的抑制作用与乳杆菌活菌制剂的抑制作用相近。结论德氏乳酸杆菌裂解物在体内外对金黄色葡萄球菌、大肠埃希菌均有较强的抑制作用。     

乳酸杆菌代谢产物对一些常见菌黏附阴道上皮细胞的抑制作用的初步探讨

目的 探讨乳酸杆菌代谢产物对大肠埃希菌、铜绿假单胞菌、金黄色葡萄球菌和白色念珠菌黏附阴道上皮细胞的抑制作用.方法 刮取健康妇女阴道上皮细胞进行体外培养,观察在乳酸杆菌代谢产物的干预下大肠埃希菌、铜绿假单胞菌、金黄色葡萄球菌和白色念珠菌黏附阴道上皮细胞的情况.结果 和结论 乳酸杆菌代谢产物能够明显抑制大肠埃希菌、铜绿假单胞菌、金黄色葡萄球菌和白色念珠菌对阴道上皮细胞的黏附.     

片球菌素PediocinPA-1抑菌活性检测

目的检测通过基因工程获得的片球菌素Pediocin PA-1抑菌活性。方法采用琼脂扩散法检测片球菌素Pediocin PA-1对单核细胞增生李斯特杆菌、金黄色葡萄球菌、铜绿假单胞菌、沙门菌和大肠埃希菌O157的抑菌活性。结果片球菌素Pediocin PA-1对单核细胞增生李斯特杆菌、金黄色葡萄球菌、沙门菌、铜绿假单胞菌和大肠埃希菌O157等均有抑制作用。其中对单核细胞增生李斯特杆菌、沙门菌、大肠埃希菌和金黄色葡萄球菌的抑制作用效果明显,对铜绿假单胞菌有微弱的抑制作用。结论通过基因工程获得的片球菌素Pediocin PA-1具有抑菌活性。     

急性肾盂肾炎合并尿路感染危险因素与致病微生物特点的临床分析

目的探讨急性肾盂肾炎合并尿路感染危险因素与致病微生物的特点。方法选择2017年4月-2018年4月在本院肾内科就诊的急性肾盂肾炎合并尿路感染患者59例,无菌操作收集患者中段尿,导管收集患者膀胱尿。2 h内送检,采用定量接种的方法,将一定量混匀未离心尿液用接种环接种于血平板或麦康凯平板进行细菌培养。相关性分析采用Pearson相关性检验。结果糖尿病、肺部感染、尿路结石、脑血管疾病和肿瘤是常见的急性肾盂肾炎(APN)合并尿路感染的危险因素。男性中段尿检出率较高的菌种有大肠埃希菌(E. coli)、金黄色葡萄球菌(S. aureus)等;膀胱尿中检出率较高的菌种有大肠埃希菌(E. coli)、肺炎克雷伯菌(K. pneumoniae)。女性中段尿和膀胱尿中检出率较高的菌种均是大肠埃希菌(E. coli)和金黄色葡萄球菌(S. aureus)。女性总住院时间≥4 d的患者比例明显高于男性。APN患者中合并糖尿病与大肠埃希菌(E. coli)和粪肠球菌(E. faecalis)存在正相关,尿路结石与大肠埃希菌(E. coli)、肺炎克雷伯菌(K. pneumoniae)、屎肠球菌(E. faecium)存在正相关。结论患者尿液中大肠埃希菌(E. coli)最常见,女性APN患者更容易并发尿路感染,住院时间长于男性患者。合并糖尿病的患者更容易患有大肠埃希菌(E. coli)和粪肠球菌(E. faecalis)感染,合并尿路结石的患者更倾向于大肠埃希菌(E. coli)、肺炎克雷伯菌(K. pneumoniae)、屎肠球菌(E. faecium)感染。     

不同浓度酒精对两种常见细菌生物膜的影响

目的 探讨不同浓度的酒精对金黄色葡萄球菌和大肠杆菌生物膜形成的抑制作用.方法 配制不同浓度的酒精(1.25％、2.5％、5％和10％),作用于培养24 h形成成熟生物膜的金黄色葡萄球菌和大肠埃希菌,利用FDA/PI荧光染料染色,在激光共聚焦显微镜扫描生物膜并分析活菌与死菌比例.结果 不同浓度的酒精对两种细菌生物膜的形成均有一定破坏作用,5％、10％浓度酒精对金黄色葡萄球菌生物膜破坏最大,活菌与死菌比例为0.142 ±0.007、0.006±0.001;10％浓度酒精对大肠埃希菌生物膜破坏最大,活菌与死菌比例为5.751±1.779.结论 较低浓度的酒精可抑制金黄色葡萄球菌和大肠埃希菌生物膜的形成,且10％浓度的酒精效果最好.     

Induction of antibacterial activity in larvae of the blowfly Lucilia sericata by an infected environment

Maggot debridement therapy (MDT) is a method for the treatment of intractable, infected and necrotic wounds. In MDT, sterile larvae of Lucilia sericata Meigen (Diptera: Calliphoridae) are applied to infected wounds, where they exert antibacterial effects. Once the larvae are placed in the wound, they are no longer germ-free. This study analysed the influence of infected environments on larval antibacterial activities. Sterile larvae were mixed in a test tube containing a bacterial suspension of Staphylococcus aureus or Pseudomonas aeruginosa, transferred to liver puree agar, and incubated at 25 °C for set periods. To collect the larval extracts, the incubated larvae were transferred to a test tube containing phosphate buffered saline (PBS), cut into multiple pieces with scissors, and centrifuged. The supernatant was used to test antibacterial activities. The results showed that infected larvae had better antibacterial capacities than sterile larvae. Antibacterial activities were induced by pretreatment with a single bacterial species, S. aureus or P. aeruginosa, within 24 h and 12 h, respectively, and disappeared after 36 h. The activities were effective against S. aureus, but not against P. aeruginosa. This natural infection model is very similar to the clinical wound context in MDT and will be a powerful tool with which to study the antibacterial activities of L. sericata larvae in MDT.     

Detection and partial characterisation of two antibacterial factors from the excretions/secretions of the medicinal maggot Lucilia sericata and their activity against methicillin-resistant Staphylococcus aureus (MRSA)

Maggot therapy is a simple and highly successful method for cleansing infected and necrotic wounds. The use of maggots has become increasingly important in the treatment of non-healing wounds, particularly those infected with the multidrug-resistant pathogen, methicillin-resistant Staphylococcus aureus (MRSA). The increasing challenge concerning the treatment of MRSA infections and the recent finding of vancomycin-resistant strains of MRSA have elicited the search for novel antibacterial compounds and, in particular, investigations into the potent antibacterial mechanism(s) behind maggot therapy. In this study, we report that excretions/secretions (ES) from the blowfly, Lucilia sericata, exhibit potent, thermally stable, protease resistant antibacterial activity against MRSA in vitro. We describe the initial characterisation of two antibacterial factors from native ES of L. sericata. A small, <500 Da factor with significant antibacterial activity against MRSA was partially isolated using ultrafiltration techniques. The potent activity of this factor was comparable to that of native excretions/secretions. A larger, 0.5-3-kDa factor with significant activity against S. aureus was also partially characterised.     

The antibacterial activity against MRSA strains and other bacteria of a <500Da fraction from maggot excretions/secretions of Lucilia sericata (Diptera: Calliphoridae)

The application of Lucilia sericata larvae to chronic, infected wounds results in the rapid elimination of infecting microorganisms, including MRSA. Previously, we demonstrated in vitro antibacterial activity of native excretions/secretions (nES) from L. sericata and partially purified two low mass antibacterial compounds with masses of 0.5-10kDa and <500Da. The present study reports the antibacterial effects of the <500Da fraction (ES<500) on the growth and morphology of a range of bacteria, including 12 MRSA strains. Distinct morphological changes were observed in Bacillus cereus and Escherichia coli following exposure to ES<500. Flow cytometry and confocal microscopy analyses, in conjunction with turbidometric and CFU assays, revealed bacteriostatic activity of nES against S. aureus and E. coli. ES<500 also demonstrated bacteriostatic activity against S. aureus, however, bactericidal activity and the induction of a viable but non-culturable state were observed with ES<500-treated E. coli.     

Antibacterial activity in vivo and in vitro in the hemolymph of Galleria mellonella infected with Pseudomonas aeruginosa

The antibacterial activity of hemolymph from Galleria mellonella infected with entomopathogenic strain of Pseudomonas aeruginosa and non-pathogenic bacterium Escherichia coli was studied. In vivo, the antimicrobial activity appeared shortly after P. aeruginosa infection, reached the maximum level 18 h postinjection, while 30 h later only trace activity was noted. The activity induced by E. coli sustained on the high level until 48 h after infection. We also noted that the antimicrobial activity level induced by the non-pathogenic bacterium was higher in comparison to that measured in insects infected with the pathogenic strain of P. aeruginosa. The results of our in vitro studies indicated that inducible antimicrobial peptides of G. mellonella larvae were digested by P. aeruginosa elastase B. After 1 h incubation of cell-free hemolymph of immune-challenged larvae with elastase B, no antibacterial activity was observed. It was also shown that elastase B degraded synthetic cecropin B while in the presence of 6 mM EDTA antibacterial activity of cell-free hemolymph as well as cecropin B, was not changed which confirmed that the activity was abolished by the metalloprotease.     

Antimicrobial factors of hemolymph and excretion of larvae Lucilia sericata (meigen) (diptera, calliphoridae)

The present study deals with molecular nature and peculiarities of functioning of two main protective systems of larvae Lucilia sericata--the antimicrobial compounds of hemolymph and of the excretion released by feeding larvae into environmental. There are identified a number of inducible antibacterial peptides including defensins (3844, 4062, and 4117 Da), P-peptide (3043 Da), and four new polypeptides (3235, 3702, 3746, and 3768 Da) In hemolymph of the larvae submitted to bacterial infestation, by the chromatomasspectrometry methods. The excretion of larvae Lucilia sericata contains peptides analogous or identical to hemolymph antibacterial peptides (diptericins: 8882 Da and 9025 Da), high molecular compounds of peptide nature (6466 Da, 6633 Da, 5772 Da, 8631 Da, etc.) differing from the known hemolymph components and low molecular compounds (130-700 Da). Spectrum of excretion bactericidal activity includes various groups of bacterial including the most actual pathogen from medical point of view--the meticillin-resistant Staphylococcus aureus, unlike the hemolymph that does not have antistaphylococcal activity. The excretion components suppressing growth and development of this staphylococcus are represented by substances of the low molecular nature (from 160 to 1020 Da). The performed studies characterize the strategies used by "surgical maggots" for protection from pathogens and for suppression of microbial competitors and allow better understanding of molecular mechanisms of larval therapy of purulent infectious diseases. These studies in perspective can serve the basis for creation of the principally new drugs for struggle with usual and antibiotics-resistant bacterial infections.     

Antibacterial properties of larval secretions of the blowfly, Lucilia sericata

The antibacterial properties of secretions aseptically collected from larvae of the greenbottle fly Lucilia sericata (Meigen) (Diptera: Calliphoridae) were examined. These investigations revealed the presence of small (<1 kDa) antibacterial factor(s) within the larval secretions, active against a range of bacteria. These include the Gram-positive Staphylococcus aureus, both methicillin-resistant Staphylococcus aureus (MRSA) and methicillin-sensitive Staphylococcus aureus (MSSA), Streptococcus pyogenes and to a lesser extent the Gram-negative Pseudomonas aeruginosa. These secretions were shown to be highly stable as a freeze-dried preparation and, considering the activity against organisms typically associated with clinical infection, may be a source of novel antibiotic-like compounds that may be used for infection control and in the fight against MRSA.     

Antimicrobial compounds from the excretions of surgical maggots, Lucilia sericata (Meigen) (Diptera, Calliphoridae)

Maggots of Lucilia sericata are widely used in the therapy of infected wounds and skin ulcers. Antimicrobial materials released by the insects during their feeding period in order to suppress microbial competitors and potential pathogens play the key role both in the maggots’ survival in their natural habitats (animal corpses) and their therapeutic efficacy. Although the antimicrobial activity of the maggots’ excretion was demonstrated about a hundred years ago, little is known about the nature of its active compounds. We studied the structural characteristics and antimicrobial activities of the compounds released by L. sericata maggots into the environment. To isolate the compounds, excretion was collected from the culture of actively feeding last instar larvae, active compounds were purified using a combination of liquid chromatography and antibacterial growth inhibition assay and characterized by mass spectrometry. Two groups of antibacterial compounds were isolated from the excretion: polypeptides with molecular masses ranging from 6466 to 9025 Da and small molecules with molecular masses ranging from 130 to 700 Da. The polypeptides characterized by the masses of 8882 and 9025 Da and showing selective activity against Gram-negative bacteria correspond well to diptericins, antimicrobial peptides previously found in the hemolymph of Calliphoridae maggots and known to be part of immune response to bacterial pathogens. Other high-molecular compounds with masses 6466, 6633, 5772, and 8631 Da have no clear analogs among antimicrobial peptides present in the hemolymph. The nature of small molecules present in the excretion awaits further study. Thus, the diversity of antimicrobial compounds discovered in Lucilia excretion demonstrates a sophisticated strategy that helps the maggots to fight bacteria and other microorganisms settling their environment. The strategy combines secretion of a set of antibacterial peptides involved in insect immune response as well as molecules which function outside the host organism.     

Antibacterial substances of low molecular weight isolated from the blowfly, Lucilia sericata

Low molecular weight compounds were isolated by high-performance liquid chromatography from the maggot or haemolymph extracts of Lucilia sericata (Meigen) (Diptera: Calliphoridae). Using gas chromatography-mass spectrometry analysis, three compounds were obtained: p-hydroxybenzoic acid (molecular weight 138 Da), p-hydroxyphenylacetic acid (molecular weight 152 Da) and octahydro-dipyrrolo[1,2-a;1',2'-d] pyrazine-5,10-dione (molecular weight 194 Da), also known as the cyclic dimer of proline (or proline diketopiperazine or cyclo[Pro,Pro]). All three molecules revealed antibacterial activity when tested against Micrococcus luteus and/or Pseudomonas aeruginosa, and the effect was even more pronounced when these molecules were tested in combination and caused lysis of these bacteria.     

羟基酪醇抑菌活性及抑菌稳定性研究

本研究探究了羟基酪醇对大肠杆菌、金黄色葡萄球菌、铜绿假单胞杆菌和枯草芽孢杆菌等四种供试菌的抑菌活性及抑菌稳定性。采用试管半倍稀释法确定MIC和MBC,并探讨羟基酪醇对供试菌的生长和细胞膜完整性的影响以及在不同介质下的抑菌稳定性。结果表明,羟基酪醇对大肠杆菌、金黄色葡萄球菌、铜绿假单胞杆菌和枯草芽孢杆菌的MIC分别为0.625、0.625、1.250、2.500 mg/mL,MBC分别为1.250、1.250、2.500、5.000 mg/mL。与对照组相比,四种供试菌核酸和可溶性蛋白泄漏显著,细胞膜的完整性被破坏。在不同NaCl浓度下,羟基酪醇对枯草芽孢杆菌的抑菌活性稳定;在1.0%和2.0%NaCl浓度下,羟基酪醇对大肠杆菌和铜绿假单胞杆菌的抑菌活性稳定;在2.0%NaCl介质下低浓度的羟基酪醇对金黄色葡萄球菌的抑菌活性稳定,在0.5%、1.5%和2.0%NaCl介质下高浓度的羟基酪醇对金黄色葡萄球菌的抑菌活性稳定。在蔗糖介质中,羟基酪醇对四种供试菌的抑菌活性均不稳定。因此,羟基酪醇可以作为一种新型的防腐剂。